Biologic Wars: Rheumatology Debate SeriesEp 4 of 4
Why Cheaper Humira Alternatives Face Resistance

Hosted by Sarah Mitchell & James Carter

0:000:00
InfographicFlashcards

More from: Biologic Wars: Rheumatology Debate Series

The ORAL Surveillance JAK Inhibitor Controversy
RheumatologyEP 1 OF 4
The ORAL Surveillance JAK Inhibitor Controversy

Sarah Mitchell & James Carter

1 minListen
Chasing Absolute Zero In Rheumatoid Arthritis
RheumatologyEP 2 OF 4
Chasing Absolute Zero In Rheumatoid Arthritis

Sarah Mitchell & James Carter

1 minListen
Stopping Spinal Fusion Or Protecting The Gut?
RheumatologyEP 3 OF 4
Stopping Spinal Fusion Or Protecting The Gut?

Sarah Mitchell & James Carter

1 minListen
Key Takeaways
  • Biosimilars are approved to stringent regulatory standards - approved biosimilars are not inferior products
  • NOR-SWITCH and multiple subsequent studies consistently show switching from reference biologic to biosimilar is safe and maintains remission
  • The nocebo effect is real - patient counselling about biosimilar equivalence is a clinical responsibility that directly affects discontinuation rates
  • NHS England biosimilar adoption reduced adalimumab spend by more than 50% while treating more patients; this dividend funded access to newer on-patent biologics
Save as PDF
Reviewed & published by
Cite This Article

Team TLSFE. Why cheaper humira alternatives face resistance. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/rheumatology/arthritis-rheumatoid/insights/why-cheaper-humira-alternatives-face-resistance.

Licence & Rights

© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.

Podcast Disclaimer
Editorial & AI Standards

All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.

Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.

References

[1] Jorgensen KK et al. NOR-SWITCH. Lancet. 2017;389:2304-2316

[2] NHS England. Biosimilar medicines: a guide for primary care. 2022

[3] Kay J et al. Ann Rheum Dis. 2018;77:1658-1665

[4] Smolen JS et al. EULAR RA Recommendations 2023. Ann Rheum Dis. 2023